US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Silverback Therapeutics, Inc.
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 08, 2022
From
Silverback Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SBTX
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
July 21, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
May 17, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
March 31, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
February 24, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 03, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
November 12, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
November 12, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
November 11, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
October 05, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
September 16, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
September 13, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
August 03, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers
July 07, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
June 15, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports First Quarter 2021 Financial Results
May 13, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
April 08, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
